Leu29-Pro245, with C-terminal Human IgG1 Fc
60-70kDa
PBS, pH7.4
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
1. A I Chapoval et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.Nat Immunol. 2001 Mar;2(3):269-74.
B7 homolog 3 (B7-H3, CD276) is a member of the B7 family of cell surface ligands that regulate T cell activation and immune responses. B7-H3 protein contains two extracellular Ig-like V-type domains and two IgG-like C2-type domains, a transmembrane domain, and a short intracellular domain. Early research examining the biological process of B7-H3 suggested that B7-H3 is a positive regulator of T cell response. Subsequent research studies indicated that B7-H3 is a negative regulator of T cell response, and that the protein inhibits T cell proliferation. One possibility is that B7-H3 interacts with two distinct sets of receptors, resulting in seemingly opposite biological outcomes. B7-H3 is expressed by antigen presenting cells, activated T cells, and a few normal tissues, including placenta and prostate. Expression of B7-H3 is seen in several cancer types, including prostate, breast, colon, lung, and gastric cancers, and in endothelial cells from tumor associated vasculature.
2e5 of transient transfected anti-B7-H3 ScFv CAR-293 cells were stained with 0.01ug B7-H3/CD276 Fc Chimera Protein, Human , (Cat. No. UA010607) and Goat Anti-Human IgG, Fcγ Fragment Specific and unrelated protein (Fig. C and B and D), and non-transfected 293 cells were used as a control (Fig. A). Alexa Fluor® 647 signal was used to evaluate the binding activity.
2e5 of transient transfected anti-B7-H3 ScFv CAR-293 cells were stained with isotype and Whitlow/218 Linker-Alexa Fluor® 488 (Fig. F and E). Alexa Fluor® 488 signal was used to evaluate the binding activity.
1μg (R: reducing conditions, N: non-reducing conditions).
Immobilized B7-H3/CD276 Fc Chimera Protein, Human (Cat. No. UA010607) at 2.0μg/mL (100μL/well) can bind Biotinylated Anti-Human B7-H3 (Enoblituzumab) with EC50 of 5.16-8.03ng/mL.